Case Report
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 7, 2006; 12(5): 809-811
Published online Feb 7, 2006. doi: 10.3748/wjg.v12.i5.809
First report of a de novo germline mutation in the MLH1 gene
Rein P Stulp, Yvonne J Vos, Bart Mol, Arend Karrenbeld, Monique de Raad, Huub JC van der Mijle, Rolf H Sijmons
Rein P Stulp, Yvonne J Vos, Bart Mol, Monique de Raad, Rolf H Sijmons, Department of Clinical Genetics, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands
Arend Karrenbeld, Department of Pathology, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands
Huub JC van der Mijle, Department of Surgery, Nij Smellinghe Hospital, PO Box 20200, 9200 DA Drachten, The Netherlands
Correspondence to: Rein P Stulp, Department of Clinical Genetics, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands. r.p.stulp@medgen.umcg.nl
Telephone: +31-50-3632929 Fax: +31-50-3632950
Received: May 13, 2005
Revised: May 19, 2005
Accepted: July 15, 2005
Published online: February 7, 2006
Abstract

Hereditary non-polyposis colorectal carcinoma (HNPCC) is an autosomal dominant disorder associated with colorectal and endometrial cancer and a range of other tumor types. Germline mutations in the DNA mismatch repair (MMR) genes, particularly MLH1, MSH2, and MSH6, underlie this disorder. The vast majority of these HNPCC-associated mutations have been proven, or assumed, given the family history of cancer, to be transmitted through several generations. To the best of our knowledge, only a single case of a de novo germline MMR gene mutation (in MSH2) has been reported till now. Here, we report a patient with a de novo mutation in MLH1. We identified a MLH1 Q701X truncating mutation in the blood lymphocytes of a male who had been diagnosed with rectal cancer at the age of 35. His family history of cancer was negative for the first- and second-degree relatives. The mutation could not be detected in the patient’s parents and sibling and paternity was confirmed with a set of highly polymorphic markers. Non-penetrance and small family size is the common explanation of verified negative family histories of cancer in patients with a germline MMR gene mutation. However, in addition to some cases explained by non-paternity, de novo germline mutations should be considered as a possible explanation as well. As guidelines that stress not to restrict MMR gene mutation testing to patients with a positive family history are more widely introduced, more cases of de novo MMR gene germline mutations may be revealed.

Keywords: MLH1; de novo; HNPCC; Germline mutation